{
  "functional_evidence_assessment": [
    {
      "variant_id": {
        "Gene": "SNCA",
        "Protein_Change": {
          "ref": "A",
          "alt": "P",
          "position": "30"
        },
        "variant_string_id": "SNCA A30P"
      },
      "functional_evidence_aim": "Pathogenic",
      "assessment_steps": [
        {
          "step_name": "Step 1: Define the disease mechanism",
          "extracted_paper_info": "Mutations in α-synuclein are linked to autosomal dominant PD. A30P mutation leads to synucleinopathy, affecting dopaminergic neurons and neurotransmitter content.",
          "judgment": "Yes",
          "reasoning": "The paper clearly defines the disease mechanism relevant to α-syn mutations."
        },
        {
          "step_name": "Step 2: Evaluate applicability of general classes of assay used in the field",
          "extracted_paper_info": "Assays include transgenic deposition, neurotransmitter content evaluation, ultrastructural changes, and behavioral analysis.",
          "judgment": "Yes",
          "reasoning": "These assays are relevant to PD pathogenesis involving dopaminergic dysfunction."
        },
        {
          "step_name": "Step 3: Evaluate validity of specific instances of assays",
          "extracted_paper_info": "Controls include wild-type mice, experiments repeated across multiple animals.",
          "judgment": "Yes",
          "reasoning": "Basic controls and replicates are sufficient, with proper use of wild-type as control."
        }
      ],
      "final_evidence_strength": {
        "type": "Pathogenic",
        "strength": "PS3_very_strong"
      },
      "overall_conclusion": "The A30P mutation in α-synuclein consistently shows functional impairments across multiple experimental approaches, strongly supporting its pathogenic role."
    }
  ]
}